TL;DR
SNC is established as a safe and effective nanocarrier system, capable of improving sorafenib bioavailability and reducing toxicity for enhanced HCC management.
Conventional paclitaxel (PTX) chemotherapy for hepatocellular carcinoma (HCC) is severely restricted by insufficient tumor-targeting specificity, unsatisfactory therapeutic efficacy, and marked systemic toxicity. To address these drawbacks, a redox-responsive and liver-targeted nanoplatform was designed for efficient P...
Hepatocellular carcinoma (HCC) is one of the most aggressive cancers with limited therapeutic efficacy and high drug resistance. This study developed a biocompatible dual-drug delivery system based on layer-by-layer liquid crystalline nanoparticles (LbL-LCNPs) co-loaded with resveratrol (RES) and hydroxychloroquine (...
ChNPs can deliver anticancer drugs to thyroid carcinoma cells with greater selectivity by utilizing both active targeting through ligand-mediated interactions and passive targeting through the increased permeability and retention effect.
Background/objective: Osimertinib, an EGFR-targeted agent approved for metastatic NSCLC, shows promise for triple-negative breast cancer due to EGFR overexpression in aggressive tumors. However, oral administration limits tumor delivery and causes systemic side effects. This study aimed to develop chitosan-coated PLGA...
Improved Cabozantinib delivery via Cabozantinib-loaded poly(lactic-co-glycolic acid) nanoparticles, prepared by solvent evaporation represents improved Cabozantinib delivery via Cabozantinib-loaded poly(lactic-co-glycolic acid) nanoparticles that overcomes pharmacokinetic pitfalls of CBZT.
The potential of advanced drug delivery systems to overcome bioavailability limitations of anticancer agents and support their further development for safer and more effective chemotherapy is highlighted.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
